If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
107.00    -2.80 (-2.55%)
Bid:
107.40
Ask:
109.40
Spread: 2.00 (1.862%)
Market Cap: £650.77m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Publication of Circular

12 Feb 2026 12:00

RNS Number : 8065S
Syncona Limited
12 February 2026
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

12 February 2026

 

Syncona Limited

 

("Syncona" or the "Company")

 

Publication of Circular

 

On 21 October 2025, Syncona announced a set of proposals which seek to maximise value for its shareholders and to create a sustainable longer-term structure for all key stakeholders. These proposals included a new investment objective and policy (the "New Investment Policy"), a new capital allocation policy (the "New Capital Allocation Policy"), and a commitment to consult with shareholders on new long-term incentive arrangements for team members of its investment manager, Syncona Investment Management Limited ("SIML") (the "Long-Term Incentive Arrangements" and together, the "Proposals").

 

An explanatory circular containing details of the Proposals, including the full text of the New Investment Policy and the New Capital Allocation Policy and details of the Long-Term Incentive Arrangements, and a notice convening the General Meeting (the "Circular") is available electronically on Syncona's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/.

 

Following consultation with shareholders, Syncona's board of directors (the "Board") has made two refinements to its proposed capital allocation policy as referred to in the October 2025 announcement, namely:

 

· the Board has committed to consulting on a new investment policy and capital allocation policy at the earliest of returning £250 million to shareholders or two years from the date of approval of the New Investment Policy; and

 

· in addition to the New Investment Policy permitting investments in new early-stage companies of no more than 5% of the Company's reported NAV as at 30 September 2025, the Company intends to limit investments in such new early-stage companies to £15 million per annum for each of the two years ended 30 September 2026 and 2027.

 

The Long-Term Incentive Arrangements proposed by the Board, following consultation with shareholders and support from Syncona's advisers, seek to:

 

· align with the New Investment Policy by linking reward to the realisation of portfolio assets, differentiating the new arrangements from the existing long-term incentive plan which is linked to NAV appreciation;

 

· incentivise SIML to deliver realised returns at values that underpin NAV to encourage a narrowing of the current share price discount and not reward poor realisation outcomes;

 

· align incentives with the Company's share price without diluting shareholders. Some payments under the Long-Term Incentive Arrangements will be applied by SIML to acquire ordinary shares in Syncona in the market to settle the payments of bonuses to SIML team members, increasing the SIML team's ongoing equity exposure. Any shares will be purchased in the market meaning that shareholders will not suffer dilution. Such shares will also be subject to lock-up arrangements;

 

· retain the life-science investment, clinical and transaction expertise of the SIML team which, when combined with its knowledge of the Company's current assets, is important for the optimisation of NAV growth and realisation values;

 

· address the overlap with existing long-term incentive plan arrangements, which cannot be terminated. The new Long-Term Incentive Arrangements include a profit share cap to limit the overall payments that can be made to the SIML team; and

 

· benchmark arrangements to other listed funds in comparable situations.

 

In accordance with the UK Listing Rules and the Company's articles of incorporation, implementation of the New Investment Policy is conditional upon shareholders' approval. Therefore, the Company announces today that it is convening a general meeting (the "General Meeting") for the purposes of seeking shareholder approval for the New Investment Policy and, by way of an advisory vote, the Long-Term Incentive Arrangements (together, the "Resolutions").

 

The General Meeting will take place at the offices of Citco Fund Services (Guernsey) Limited, Frances House, Sir William Place, St Peter Port, Guernsey GY1 3RD, Channel Islands at 10.00 a.m. on 3 March 2026.

 

The Company has received a letter of intent from The Wellcome Trust Limited as trustee of The Wellcome Trust to vote in favour of the Resolutions in respect of 186,000,000 ordinary shares, representing approximately 30.582 per cent. of the total voting rights in the Company at 9 February 2026.

 

Melanie Gee, Chair of Syncona Limited, said: "My Board colleagues and I are very grateful to our shareholders for their constructive engagement in our strategic process. We believe that today's proposals provide the opportunity to support our portfolio, whilst maximising potential cash returns from our later stage assets over the short to medium term. We are also committing to consult with shareholders on revisiting the investment objective and policy after two years or the return of £250m, whichever is the earlier. Accordingly, the Board recommends shareholders vote in favour of our proposals."

 

In compliance with the UK Listing Rules, the Circular has today been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. Printed copies of the Circular are being posted to shareholders where requested.

 

Enquiries

 

Syncona

 

Annabel Clark

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

 

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

IMPORTANT NOTICES

 

This announcement or any part of it does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities.

 

Certain statements contained in this announcement constitute "forward-looking statements" with respect to the results, financial condition, performance, developments or achievements of Syncona and its subsidiaries. Words such as "believes", "anticipates", "estimates", "expects", "intends", "plans", "aims", "potential", "will", "would", "could", "considered", "likely", "estimate" and variations of these words and similar future or conditional expressions, are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. These statements and forecasts are inherently predictive, speculative and involve risks and uncertainties and assumptions that could cause actual results, financial condition, performance, developments or achievements to differ materially from those expressed or implied by these forward-looking statements and forecasts. Many of these risks, uncertainties and assumptions relate to factors that are beyond Syncona's ability to control, predict or estimate precisely. No representation or warranty is made, and no responsibility or liability is accepted, as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements. The forward-looking statements contained in this announcement speak only as of the date of this announcement. Syncona expressly disclaims any obligation or undertaking to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required to do so by applicable law or regulation, the Financial Conduct Authority or London Stock Exchange plc.

 

No statement in this announcement is intended to be a profit forecast or profit estimate for any period, and no statement in this announcement should be interpreted to mean that earnings, earnings per share or income, cash flow from operations or free cash flow for Syncona for the current or future financial years would necessarily match or exceed the historical published earnings, earnings per share or income, cash flow from operations or free cash flow for Syncona.

 

Neither the content of Syncona's website (or any other website) nor the content of any website accessible from hyperlinks on Syncona's website (or any other website) is incorporated into or forms part of this announcement.

 

This announcement has been prepared for the purposes of complying with applicable law and regulation in the United Kingdom and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws and regulations of any jurisdiction outside the United Kingdom.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CIRGPUMWPUPQGGP
Date   Source Headline
3rd Jul 20267:00 amRNSNotice of AGM
3rd Jul 20267:00 amRNSHolding(s) in Company
30th Jun 20267:00 amRNSHolding(s) in Company
22nd Jun 20267:00 amRNSDirector/PDMR Shareholding
18th Jun 20267:03 amRNSFinal Results
17th Jun 20267:00 amRNSDirectorate change
19th May 20263:00 pmRNSHolding(s) in Company
18th May 20263:30 pmRNSHolding(s) in Company
7th May 20266:25 pmRNSHolding(s) in Company
16th Mar 20262:16 pmRNSHolding(s) in Company
16th Mar 20262:16 pmRNSHolding(s) in Company
3rd Mar 202611:00 amRNSResults of General Meeting and Board Changes
3rd Mar 20269:30 amRNSQuell Clinical Updates
12th Feb 202612:00 pmRNSPublication of Circular
5th Feb 20267:00 amRNSThird Quarter Update
8th Jan 202612:01 pmRNSBeacon raises $75m in oversubscribed Series C
28th Nov 20256:00 pmRNSTotal Voting Rights
17th Nov 20257:00 amRNSIssue of shares pursuant to incentive scheme
13th Nov 20257:00 amRNSHalf-year Report
12th Nov 20254:30 pmRNSAutolus reports Q3 2025 Financial Results
21st Oct 20257:00 amRNSStrategy update
18th Sep 20255:30 pmRNSHolding(s) in Company
4th Sep 20251:05 pmRNSBeacon positive interim data for Phase 2 studies
13th Aug 20254:30 pmRNSAutolus reports Q2 2025 Financial Results
7th Aug 20257:00 amRNSFirst Quarter Update
5th Aug 20252:07 pmRNSDirectorate Change
5th Aug 20252:06 pmRNSResult of AGM
2nd Jul 20257:00 amRNSNotice of AGM
1st Jul 20259:36 amRNSTotal Voting Rights
19th Jun 20257:00 amRNSFinal Results
19th Jun 20257:00 amRNSStrategy Update
19th Jun 20257:00 amRNSTransaction in Own Shares
18th Jun 20257:00 amRNSTransaction in Own Shares
17th Jun 20257:00 amRNSTransaction in Own Shares
16th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20257:00 amRNSTransaction in Own Shares
12th Jun 20251:00 pmRNSAutolus Data Updates
12th Jun 20257:00 amRNSTransaction in Own Shares
11th Jun 20257:00 amRNSTransaction in Own Shares
10th Jun 20257:00 amRNSTransaction in Own Shares
9th Jun 20257:00 amRNSTransaction in Own Shares
6th Jun 20254:32 pmRNSHolding(s) in Company
5th Jun 20257:00 amRNSTransaction in Own Shares
4th Jun 20257:00 amRNSTransaction in Own Shares
3rd Jun 20257:00 amRNSTransaction in Own Shares
2nd Jun 202511:35 amRNSTotal Voting Rights
2nd Jun 20257:00 amRNSTransaction in Own Shares
30th May 20257:00 amRNSTransaction in Own Shares
29th May 20257:00 amRNSTransaction in Own Shares
28th May 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.